Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. Matsue, Y.; Kagiyama, N.; Yoshida, K.; Kume, T.; Okura, H.; Suzuki, M.; Matsumura, A.; Yoshida, K.; and Hashimoto, Y. Journal of Cardiac Failure, 21(11):859--864, November, 2015.
doi  abstract   bibtex   
BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented. METHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality. RESULTS: Of all of the AHF patients included in this study, 402 (38.7%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95% CI 1.54-5.91). CONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.
@article{matsue_carperitide_2015,
	title = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}: {A} {Propensity} {Score}-{Matched} {Analysis}},
	volume = {21},
	issn = {1532-8414},
	shorttitle = {Carperitide {Is} {Associated} {With} {Increased} {In}-{Hospital} {Mortality} in {Acute} {Heart} {Failure}},
	doi = {10.1016/j.cardfail.2015.05.007},
	abstract = {BACKGROUND: Carperitide (α-human A-type natriuretic peptide) has been used for more than one-half of all acute heart failure (AHF) patients in Japan. However, its clinical effectiveness is not well documented.
METHODS: We retrospectively identified AHF patients presenting with acute onset or worsening of symptoms and admitted to 1 of the 3 participating hospitals. Propensity score-matched analysis was performed. The primary end point was in-hospital mortality.
RESULTS: Of all of the AHF patients included in this study, 402 (38.7\%) were treated with carperitide, and in-hospital mortality rate for the total cohort was 7.6\%. We matched 367 pairs of patients treated with and without carperitide according to propensity score. In this matched cohort, treatment with carperitide was associated with in-hospital mortality (odds ratio [OR] 2.13, 95\% confidence interval [CI] 1.17-3.85; P = .013). Potentially more harmful effects were observed in elderly patients (OR 2.93, 95\% CI 1.54-5.91).
CONCLUSIONS: Carperitide was significantly associated with increased in-hospital mortality rate in AHF patients. Our results strongly suggest the necessity for well designed randomized clinical trials of carperitide to determine its clinical safety and effectiveness.},
	language = {eng},
	number = {11},
	journal = {Journal of Cardiac Failure},
	author = {Matsue, Yuya and Kagiyama, Nobuyuki and Yoshida, Kazuki and Kume, Teruyoshi and Okura, Hiroyuki and Suzuki, Makoto and Matsumura, Akihiko and Yoshida, Kiyoshi and Hashimoto, Yuji},
	month = nov,
	year = {2015},
	pmid = {25999241},
	keywords = {Acute heart failure, Drug Therapy, Prognosis, vasodilator},
	pages = {859--864}
}
Downloads: 0